Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 37.32B | 58x | CHF 528.80 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.1% Upside | Upgrade to Pro+ | ||
Lonza Group | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 37.32B | 58x | CHF 529 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.1% Upside | Upgrade to Pro+ | ||
BACHEM HOLDING AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 3.57B | 29.7x | 4.11 | CHF 47.56 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.1% Upside | Upgrade to Pro+ | |
BB Biotech | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 1.46B | 19.3x | 0.14 | CHF 26.65 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 1.42B | 0.14 | CHF 25.35 | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Kuros Biosciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 679.49M | -177.5x | -2.57 | CHF 17.86 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Basilea Pharmaceutica AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 489.46M | 6.3x | 0.01 | CHF 40.35 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Idorsia | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 235.50M | -0.7x | -0.07 | CHF 1.05 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.9% Downside | Upgrade to Pro+ | |
Bioversys Ag | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 202.15M | CHF 35 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Newron Pharmaceuticals | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 127.34M | 8.1x | 0.04 | CHF 6.38 | 5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Molecular Partners AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 118M | -2x | -0.14 | CHF 3.20 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xlife Sciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 111.39M | 11.8x | 0.3 | CHF 20.30 | 4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 30.79M | -1.8x | -0.02 | CHF 2.45 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Addex Therapeutics Ltd | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 4.72M | -0.4x | -0 | CHF 0.05 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |